P1.13-10 Aurora Kinase a Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.867
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer

Cancer Research
Cancer ResearchOncology
2019English

Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790m-Mutant Lung Cancer

Annals of Oncology
MedicineOncologyHematology
2019English

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy
OncologyPharmacology
2016English

WZ4002, a Third-Generation EGFR Inhibitor, Can Overcome Anoikis Resistance in EGFR-mutant Lung Adenocarcinomas More Efficiently Than SRC Inhibitors

Laboratory Investigation
Forensic MedicinePathologyCell BiologyMolecular Biology
2011English

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

Current Oncology
Oncology
2012English

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

Current Oncology
Oncology
2012English

CD44 Facilitates Epithelial to Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer

Oncology in Clinical Practice
Oncology
2019English

Molecular Imaging for Detection of Sensitivity and Resistance to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Clinical and Translational Imaging
Nuclear MedicineRadiologyImaging
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy